Big pharma, Partnering, Pharma

Pharma partners, Menarini and Oxford Biotherapeutics, invest $1.1 billion in AML drug candidate

Posted on 10 December 2013

Tags: , , , ,

In October 2012, Pharma partners, Menarini and Oxford BioTherapeutics announce a strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.

For five of OBT’s antibody and antibody drug conjugate (ADC) programs, each of which addresses a different cancer indication via a different novel oncology target.

Menarini will lead the efforts in the manufacture and clinical development of each program.

OBT will provide the proprietary cancer target, antibody and arming technologies.

Once clinical proof of concept has been achieved, OBT will complete the clinical development and commercialise these novel antibody-based products in North America and Japan.

Menarini will develop and commercialise the products in Europe, CIS, Asia and Latin America.

The pharma partners have designated a novel enhanced antibody targeting acute myeloid leukemia as the first clinical development candidate under the companies' strategic oncology collaboration.

The companies have initiated formal regulatory enabling studies to support an application for a clinical phase I trial in AML patients.

Menarini contributes manufacturing, regulatory, pre-clinical, clinical and expertise, supported by investment of up to $1.1 billion.

Menarini is responsible for the clinical development, first up to the clinical proof of concept study, then to the full development and regulatory approval.

The first of the programs to progress into clinical development is an engineered antibody designed to induce antibody-dependent cellular cytotoxicity (ADCC) in AML and related hematological cancers.

The manufacturing process has been transferred and scaled-up at Menarini Biotech.

Further regulatory pre-clinical studies and ex vivo experiments on AML blasts are now underway by Menarini.

Read the full article at PR Newswire

For further deal information visit Current Agreements (subscription required)

 

Related

Report: Oncology Partnering Terms and Agreements

Report: Partnering Deals and Alliances with Menarini

Report: Antibody Partnering Terms and Agreements

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
a1banner300x150animgif